Difference between revisions of "Amrubicin (Calsed)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Intravenous chemotherapy" to "Category:Intravenous medications") |
m |
||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
Class/mechanism: Synthetic third generation anthracycline and topoisomerase II inhibitor.<ref>[http://www.ds-pharma.com/news/prior/sumitomo_2002/20021206.html Sumitomo Pharmaceuticals Co. press release about launch of amrubicin (Calsed) on 12/6/2002]</ref><ref>[http://www.ds-pharma.com/news/2012/20120905.html Dainippon Sumitomo Pharma submits an application for anticancer antibiotic amrubicin HCI (Brand name in Japan: CALSED®) in China, 9/5/2012]</ref> | Class/mechanism: Synthetic third generation anthracycline and topoisomerase II inhibitor.<ref>[http://www.ds-pharma.com/news/prior/sumitomo_2002/20021206.html Sumitomo Pharmaceuticals Co. press release about launch of amrubicin (Calsed) on 12/6/2002]</ref><ref>[http://www.ds-pharma.com/news/2012/20120905.html Dainippon Sumitomo Pharma submits an application for anticancer antibiotic amrubicin HCI (Brand name in Japan: CALSED®) in China, 9/5/2012]</ref> | ||
| Line 39: | Line 37: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| − | |||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| Line 45: | Line 42: | ||
[[Category:Topoisomerase inhibitors]] | [[Category:Topoisomerase inhibitors]] | ||
[[Category:Small cell lung cancer medications]] | [[Category:Small cell lung cancer medications]] | ||
| + | |||
| + | [[Category:PMDA approved drugs]] | ||
Revision as of 01:38, 9 October 2017
General information
Class/mechanism: Synthetic third generation anthracycline and topoisomerase II inhibitor.[1][2]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
Clinical trials
- Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer
- Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
- AMR PH GL 2007 CL 001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy
- A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer
- A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.
- Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer
- Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.
- Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy
- A Phase II Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
- Phase I/II Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma
- Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma (ARSARC-PI-0010)
- Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma
- Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer
- Amrubicin and Irinotecan in Treating Patients With Recurrent or Relapsed Extensive Stage Small Cell Lung Cancer
- Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer
- Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)
Patient drug information
No information available.
Also known as
AMR, amrubicin HCI, SM-5887.